Optimi Health Corp. (CSE: OPTI, Nasdaq: OPTH) announced on October 26, 2026, the formation of Optimi Australia Pty Ltd, a wholly owned subsidiary tasked with sales, distribution, and prescriber relationships across Australia. The company simultaneously appointed Adrian Jones, a pharmaceutical industry veteran with more than 15 years at Bristol Myers Squibb, as Director of Australian Operations. The move formalises Optimi's commercial presence in what the company describes as its first active commercial market, where its products are already being prescribed under Australia's Authorised Prescriber Scheme.
Key Points
- Optimi Health Corp. (CSE: OPTI, Nasdaq: OPTH, FSE: 8BN) is a commercial-stage psychedelic pharmaceutical manufacturer based in Vancouver, British Columbia.
- Optimi Australia Pty Ltd has been established as a wholly owned subsidiary to manage Australian distribution and business development.
- Products to be distributed include 5 mg naturally derived psilocybin capsules and 40 mg and 60 mg MDMA capsules, manufactured at Optimi's Health Canada-licensed GMP facility in Princeton, British Columbia.
- Investors may be watching how quickly Optimi Australia expands its clinic and pharmacy network under the Authorised Prescriber Scheme.
Optimi Australia Pty Ltd Formed to Lead In-Market Sales and Prescriber Outreach
The new subsidiary will serve as the operational hub for Optimi's Australian commercial activities, handling sales to clinics and pharmacies and managing prescriber relationships under the country's Authorised Prescriber Scheme. According to the release, all finished drug products sold through Optimi Australia are manufactured at the company's Health Canada-licensed Good Manufacturing Practice facility in Princeton, British Columbia. The company did not disclose financial targets or projected revenue from Australian operations in the announcement.
Adrian Jones Brings Bristol Myers Squibb Launch Experience to the Australian Role
Adrian Jones joins Optimi after more than 15 years at Bristol Myers Squibb, where he most recently served as Associate Director, Head of Sales and Marketing for the company's Australian oncology and cardiovascular portfolios. The release states he served as launch lead for first-in-class therapies including Opdivo® and Camzyos®, and held earlier psychiatry-focused roles with Eli Lilly and Hospira. CEO Dane Stevens described Jones as bringing extensive experience launching new therapies in the Australian market, citing continued growth in demand from authorised prescribers.
Psilocybin and MDMA Capsules Targeting Australia's Regulated Psychedelic Therapy Market
Optimi's product portfolio for the Australian market includes 5 mg naturally derived psilocybin capsules and 40 mg and 60 mg MDMA capsules. These products are accessible to patients through Australia's Authorised Prescriber Scheme, which the release notes remains the company's first commercial market. In Canada, the products are accessible through the Special Access Program. The company also disclosed plans to advance a Health Canada-approved Phase 2 clinical trial for psilocybin-assisted therapy for major depressive disorder and a proposed Phase 3 trial for MDMA-assisted therapy for post-traumatic stress disorder.





Please wait processing your request...